A landmark twice-yearly HIV prevention tool could be available for $40 per person per year in 120 low- and middle-income countries by 2027, major global foundations announced on Wednesday. The Gates Foundation, alongside the Clinton Health Access Initiative, is partnering with Indian pharmaceutical manufacturers to produce a generic version of Gilead’s innovative PrEP drug, which has been pivotal in reducing HIV transmission rates.
This collaboration highlights a significant shift in the global health landscape, where access to life-saving medications is increasingly prioritized. By leveraging India’s robust generic manufacturing capabilities, the initiative aims to address the affordability barriers that have historically limited access to PrEP in resource-constrained settings. The implications of this partnership extend beyond cost; they signal a commitment to equitable healthcare solutions in the fight against HIV/AIDS.
Start your 7-day trial and see what the database can do →
